美国 · SEC FORM 4
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA · NYSE · CIK 0000818686 · Healthcare · Drug Manufacturers—Specialty & Generic
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
39 同一窗口内观察到的 Form 4 交易行
22 sales · 17 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 12 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-09-05 · McAvoy David R..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 29,848,805
- 上期报告
- 31,478,314
- 日均成交量
- 5,530,389
- 回补天数
- 5.4
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-09-05 | McAvoy David R. | 买入 (P) | Ordinary Shares | 1,113 | USD 18.86 | USD 20,991 | SEC 申报 ↗ |
Form 4 申报证据
117 transaction lines in the latest 365-day window; 619 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Savage Brian | 卖出 (S) | Ordinary Shares | 7,342 | USD 38.85 | USD 285,227 | SEC 申报 ↗ |
| 2026-09-18 | Savage Brian | 期权行权／转换 (M) | Ordinary Shares | 4,503 | USD 34.70 | USD 156,254 | SEC 申报 ↗ |
| 2026-09-18 | MIGNONE ROBERTO | 卖出 (S) | Ordinary Shares | 367,600 | USD 39.06 | USD 14,358,456 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Savage Brian | 卖出 (S) | Ordinary Shares | 7,342 | USD 38.85 | USD 285,227 | SEC 申报 ↗ |
| 2026-09-18 | Savage Brian | 期权行权／转换 (M) | Ordinary Shares | 4,503 | USD 34.70 | USD 156,254 | SEC 申报 ↗ |
| 2026-09-18 | MIGNONE ROBERTO | 卖出 (S) | Ordinary Shares | 367,600 | USD 39.06 | USD 14,358,456 | SEC 申报 ↗ |
| 2026-08-21 | Weiss Amir | 卖出 (S) | Ordinary Shares | 9,445 | USD 37.62 | USD 355,276 | SEC 申报 ↗ |
| 2026-08-21 | Weiss Amir | 期权行权／转换 (M) | Ordinary Shares | 2,500 | USD 19.61 | USD 49,025 | SEC 申报 ↗ |
| 2026-08-21 | Satchi-Fainaro Ronit | 卖出 (S) | Ordinary Shares | 415 | USD 37.25 | USD 15,459 | SEC 申报 ↗ |
| 2026-08-17 | Lippman Evan | 卖出 (S) | Ordinary Shares | 18,600 | USD 36.57 | USD 680,202 | SEC 申报 ↗ |
| 2026-08-05 | Zaks Tal Zvi | 卖出 (S) | Ordinary Shares | 17 | USD 34.87 | USD 593 | SEC 申报 ↗ |
| 2026-08-03 | Jover Placid | 卖出 (S) | Ordinary Shares | 12,827 | USD 34.88 | USD 447,406 | SEC 申报 ↗ |
| 2026-08-03 | Jover Placid | 期权行权／转换 (M) | Ordinary Shares | 12,827 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-03 | Hughes Eric A | 卖出 (S) | Ordinary Shares | 25,578 | USD 34.88 | USD 892,161 | SEC 申报 ↗ |
| 2026-08-03 | Hughes Eric A | 期权行权／转换 (M) | Ordinary Shares | 52,744 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-18 | Shields Matthew | 卖出 (S) | Ordinary Shares | 9,989 | USD 32.19 | USD 321,546 | SEC 申报 ↗ |
| 2026-06-11 | Kalif Eliyahu Sharon | 卖出 (S) | Ordinary Shares | 106,563 | USD 34.10 | USD 3,633,798 | SEC 申报 ↗ |
| 2026-06-05 | Zaks Tal Zvi | 期权行权／转换 (M) | Ordinary Shares | 14,492 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-05 | Satchi-Fainaro Ronit | 期权行权／转换 (M) | Ordinary Shares | 14,492 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-05 | Nisen Perry | 期权行权／转换 (M) | Ordinary Shares | 14,492 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-05 | MIGNONE ROBERTO | 期权行权／转换 (M) | Ordinary Shares | 14,492 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-05 | Lichtenstein Chen | 期权行权／转换 (M) | Ordinary Shares | 14,492 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-05 | LIEBERMAN GERALD M | 期权行权／转换 (M) | Ordinary Shares | 14,492 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-05 | Francis Richard D | 卖出 (S) | Ordinary Shares | 6,153 | USD 34.35 | USD 211,356 | SEC 申报 ↗ |
| 2026-06-05 | Francis Richard D | 期权行权／转换 (M) | Ordinary Shares | 13,043 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-05 | Elstein Amir | 期权行权／转换 (M) | Ordinary Shares | 14,492 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-05 | Crane Rosemary A | 期权行权／转换 (M) | Ordinary Shares | 14,492 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-05 | BARER SOL J | 期权行权／转换 (M) | Ordinary Shares | 21,739 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-03 | Shields Matthew | 卖出 (S) | Ordinary Shares | 16,195 | USD 32.87 | USD 532,330 | SEC 申报 ↗ |
| 2026-06-03 | Shields Matthew | 期权行权／转换 (M) | Ordinary Shares | 16,195 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-14 | Lippman Evan | 卖出 (S) | Ordinary Shares | 41,658 | USD 35.58 | USD 1,482,192 | SEC 申报 ↗ |
| 2026-05-14 | Lippman Evan | 期权行权／转换 (M) | Ordinary Shares | 85,849 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-14 | Kalif Eliyahu Sharon | 卖出 (S) | Ordinary Shares | 153,251 | USD 35.61 | USD 5,457,268 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | TEVA |
| CIK | 0000818686 |
| 行业 | Healthcare |
| 细分行业 | Drug Manufacturers—Specialty & Generic Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | NYSE |
数据覆盖
| 本地 Form 4 历史 | 619 transaction lines from 2020-02-09 to 2026-09-18 1 P purchase lines · 239 S sale lines · 379 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.